Oruka Therapeutics, Inc.
ORKA
Rang in Aktien
#3290
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Aktienkurs
$80.01
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$5.30B
Veränderung (1 Tag)
1.16%
Veränderung (1 Jahr)
200.21%
Land
US
Handel Oruka Therapeutics, Inc. (ORKA)
Kategorie
Healthcare
EPS für Oruka Therapeutics, Inc. (ORKA)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Oruka Therapeutics, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Oruka Therapeutics, Inc. von 2005 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2025 | $-2.31 | -53.71% |
| 2024 | $-4.99 | 12.39% |
| 2023 | $-4.44 | -46.31% |
| 2022 | $-8.27 | -50.42% |
| 2021 | $-16.68 | 98.57% |
| 2020 | $-8.40 | -83.13% |
| 2019 | $-49.79 | -59.76% |
| 2018 | $-123.73 | -67.68% |
| 2017 | $-382.87 | -2.07% |
| 2016 | $-390.96 | -0.55% |
| 2015 | $-393.12 | -44.68% |
| 2014 | $-710.64 | -54.81% |
| 2013 | $-1.57K | -46.39% |
| 2012 | $-2.93K | -38.99% |
| 2011 | $-4.81K | -46.46% |
| 2010 | $-8.98K | -30.28% |
| 2009 | $-12.88K | -99.72% |
| 2008 | $-4.67M | 11,082.66% |
| 2007 | $-41.73K | -91.09% |
| 2006 | $-468.12K | 49.13% |
| 2005 | $-313.89K | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| $13.70 | - |
BE
|
